BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Advaxis, Inc. To Present At The 27th Annual ROTH Conference 3/5/2015 7:55:59 AM
Advaxis, Inc. To Present At The Cowen and Company 35th Annual Health Care Conference 3/2/2015 7:44:29 AM
Advaxis, Inc. To Present At International Anal Neoplasia Society Scientific Meeting 2015 2/26/2015 8:40:32 AM
Advaxis, Inc. Completes $23 Million Financing 2/18/2015 11:06:25 AM
Advaxis, Inc. Appoints Mayo Pujols Vice President, Manufacturing 2/13/2015 10:19:20 AM
Advaxis, Inc. Forms Clinical Trial Collaboration With Incyte Corporation (INCY) To Evaluate Investigational Combination Of Two Novel Cancer Immunotherapies For Early Stage Cervical Cancer 2/11/2015 7:56:49 AM
Gynecologic Oncology Group Phase 2 Study Of Advaxis, Inc.'s Lm-LLO Immunotherapy, ADXS-HPV, For The Treatment Of Persistent Or Recurrent Cervical Cancer Achieves Safety And Efficacy Criteria 1/28/2015 7:55:17 AM
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2 1/22/2015 9:25:13 AM
Advaxis, Inc. To Host Analyst & Investor Day On February 3, 2015 1/20/2015 7:52:48 AM
Advaxis, Inc. To Present At The Noble Financial Capital Markets 11th Annual Investor Conference 1/15/2015 7:23:18 AM
12345678910...